The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7  several new actions to promote competition in health care and support lower prescription drug costs. Among other things, the agencies will seek public input on the impact of private equity and corporate control in health care to identify areas for future regulation and enforcement; improve information sharing to better identify anticompetitive 鈥渞ollups鈥 that evade antitrust scrutiny; and appoint an HHS chief competition officer and health care chief counsels at DOJ and FTC. 

In addition, the Centers for Medicare & Medicaid Services today released  for Federally Qualified Health Centers and Rural Health Clinics and plans to seek public input early next year to strengthen data and transparency in the Medicare Advantage market, the Administration said. The Department of Commerce and HHS also proposed a framework to promote access to taxpayer-funded inventions, including medical treatments.

Related News Articles

Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and鈥
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District鈥
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that鈥
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will鈥
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by鈥